ISSN: 0973-7510

E-ISSN: 2581-690X

Mini Review | Open Access
Md. Altamash Ahmad1, Harleen Kaur1, Pratima Kumari1, Ravinder Singh1 , Rupinder Kaur1, Hitesh Chopra1, Ojus Sardana1, Talha Bin Emran2,3 and Kuldeep Dhama4
1Chitkara College of Pharmacy, Chitkara University, Punjab, India.
2Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.
3Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
4Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India.
Article Number: 8350 | © The Author(s). 2023
J Pure Appl Microbiol. 2023;17(1):12-22.
Received: 17 December 2022 | Accepted: 02 February 2023 | Published online: 02 March 2023
Issue online: March 2023

ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient chimpanzee adenovirus vectored vaccine developed by Oxford and AstraZeneca for a disease we all know as Coronavirus, or COVID-19. Ongoing clinical studies reveal that the ChAdOx1 nCoV-19 vaccine has a tolerable safety profile and is effective against symptomatic COVID-19. This vaccine may prove crucial in boosting herd immunity, averting life threatening illness, and relieving the current pandemic. In this mini review, we performed a thorough literature search through PubMed and Google Scholar and reported various case reports associated with complications of the adenovirus-vectored COVID-19 vaccine. Various adverse effects of the ChAdOx1 nCoV-19 vaccine were reported around the globe, which were often serious but rare and developed into life-threatening pathologies such as GBS, thrombocytopenia, demyelinating neuropathies, progressive dementia, cerebral infarction, IgA vasculitis, hemophagocytic lymphohistiocytosis, herpes zoster, cutaneous reactions, and vein thrombosis. These worldwide reported complications, which are usually rare and severe, will aid clinicians in understanding and managing unforeseen situations. There is a need for more research to find out more about these complications and their etiopathogenesis. However, the benefits of these vaccinations for stopping the spread of the outbreak and lowering the fatality rate outweigh the potential risk of the uncommon complications.


SARS-CoV-2, ChAdOx1 nCoV-19, Health, Complications, Thrombocytopenia

Article Metrics

Article View: 41

Share This Article

© The Author(s) 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.